首页> 外国专利> How to taxane-based anticancer agents, platinum complex-based anti-cancer agent, and sorting the effective group of cancer treatment was a combination of three types of fluoropyrimidine anti-cancer agent

How to taxane-based anticancer agents, platinum complex-based anti-cancer agent, and sorting the effective group of cancer treatment was a combination of three types of fluoropyrimidine anti-cancer agent

机译:如何以紫杉烷类抗癌药,铂类复合物为基础的抗癌药,以及有效的癌症分选方法是三种类型的氟嘧啶类抗癌药的组合

摘要

How to taxane-based anticancer agents, platinum complex-based anti-cancer agent, and sorting the effective group of cancer treatment was a combination of three types of fluoropyrimidine anti-cancer agents, as well as the present invention is that the taxane-based anti- was intended that do agent, a platinum-based complex anticancer agent, and to provide a reagent for predicting the effects of cancer therapy in combination the three fluoropyrimidine anticancer agent. PDGFB gene, PCGF3 gene, CISH gene, ANXA5 gene, ANTXR2 gene, B4GALT5 gene, PLK2 gene, ATP7B gene, FAM116A gene, HECA gene, JMJD2A gene, STYX gene, EGR1 gene, AVPI1 gene, and selected from the group consisting of ERLIN1 gene as an indicator the amount of expression product of one gene, taxane-based anticancer agents, platinum complex-based anti-cancer agents, and treatment of cancer in combination the three fluoropyrimidine anti-cancer agent is at least How to select the effective group.
机译:如何将紫杉烷类抗癌剂,铂络合物类抗癌剂以及有效的癌症分选方法归为三类氟嘧啶类抗癌剂的组合,以及本发明就是以紫杉烷类为基础抗-意在作为一种试剂,一种基于铂的复合抗癌剂,并提供一种用于预测将三种氟嘧啶抗癌剂组合使用的癌症治疗效果的试剂。 PDGFB基因,PCGF3基因,CISH基因,ANXA5基因,ANTXR2基因,B4GALT5基因,PLK2基因,ATP7B基因,FAM116A基因,HECA基因,JMJD2A基因,STYX基因,EGR1基因,AVPI1基因,并且选自ERLIN1以基因为指标的一种基因,紫杉烷类抗癌药,铂络合物类抗癌药和三种氟嘧啶类抗癌药联合治疗的基因表达量至少是如何选择有效组的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号